Illumina’s Turnaround Play: Betting On NovaSeq X Amidst Rising Competitive Tides

News Snapshot:

JuSun/iStock via Getty Images Illumina (NASDAQ:ILMN) operates in the genetic and genomic analysis sector, supplying a range of products and services to both research and clinical environments. The firm's offerings aim to streamline the integration of genomic technologies across numerous applications. The customer base of Illumina is wide-ranging, encompassing genomic research centers, academic institutions, governmental laboratories, hospitals, and entities within the pharmaceutical, biotechnology, and consumer genomics industries. Illumina's product suite includes sequencing and microarray systems, consumables, and analysis tools. This portfolio is tailored to meet the diverse requirements associated with genomic complexity, varying price sensitivities, and throughput demands. I previously...